Introduction
Plasma cell leukaemia as defined by an absolute plasma cell count of greater than 2 x 109/litre in the peripheral blood or more than 20% of the peripheral leucocytes as plasma cells' may occur in patients already suffering from multiple myeloma (about 2% will develop this complication) or may be the first presentation of a plasma cell malignancy, so-called primary plasma cell leukaemia. This is a rare condition with 49 cases reported between 1965 and 1980.1 The mean survival time between diagnosis and death is 4.9 months, although three complete remissions have been reported."5', 6 A number of treatment regimens have been suggested,12'51-6 including the conventional therapy for multiple myeloma of melphalan and prednisolone, '6, 75,17.18,26 but no single regimen has yielded consistent remissions. We describe a patient with primary plasma cell leukaemia treated with cyclical courses of oral melphalan and prednisolone effecting control of the disease in the bone marrow and an initial excellent clinical response, only to relapse with leukaemic deposits in his testes and central nervous system 14 months after diagnosis. At that time there was no objective evidence of active disease in the bone marrow.
In this case the central nervous system and testes may have acted as sanctuary sites from the effect of the chemotherapy as is seen in cases of acute lymphoblastic leukaemia in children. 23 
Case report
In November 1984 a 62 year old Caucasian male was admitted with a 6 week history of lethargy, weakness and dyspnoea on exertion. On examination he was clinically anaemic with no other abnormalities.
Investigations revealed: haemoglobin 7.8 g/dl, MCV 95.7 fl, white cell count 13.8 x 109/l, neutrophils 19%, lymphocytes 39%, monocytes 1%, eosinophils 2%, plasma cells 38%, platelets 100 x 109/1. The erythrocyte sedimentation rate was 146 mm/h. There was a monoclonal IgG ((lambda) serum paraprotein (52 g/l) with lambda BenceJones proteinuria. Blood urea and calcium, and skeletal X-rays were normal.
Bone marrow examination from a sternal aspirate revealed a hypercellular marrow virtually replaced by sheets and clumps of plasma cells some of which were well differentiated but many were larger and primitive. Erythropoeisis and myelopoeisis were both very depressed and only an occasional megakaryocyte was identified.
The initial management consisted of a blood transfusion, allopurinol 300 mg/day and courses of melphalan 15 mg/day and prednisolone 45 mg/day for 5 days every 3 weeks. He The reason why certain patients respond to chemotherapy are not clear but it may be due to the degree of differentiation of the plasma cells.l If one accepts that the tumour grows exponentially a rapid response to treatment is a poor prognostic sign,27 in that patients with multiple myeloma who showed a rapid response to treatment relapsed quickly and at two years after diagnosis only 39% survived compared to 78% surviving at two years who had shown a slow response. This may explain the reason for and nature of the relapse in this case.
There is good evidence from the bone marrow samples, peripheral blood counts and immunoglobulin levels that the treatment significantly reduced the tumour mass in the bone marrow, however there must have been at least as many residual tumour cells in the bone marrow as seen in other acute leukaemias in remission. Similarly small numbers of tumour cells, not recognized in routine differential counts, may well have continued to circulate and these cells may have become trapped or homed-into the so-called sanctuary sites of the testes and central nervous system. These are recognized sites for deposits of plasma cell leukaemia9 2"17 28 32 and may occur despite a good clinical and haematological response to treatment.9" 1, 17 There is an anatomical blood-brain barrier which is poorly penetrated by the use of intravenous melphalan '9,20,21,22 and results in the brain acting as a sanctuary from chemotherapeutic attack. In acute lymphoblastic leukaemia specific measures are taken to attempt to control the disease process in the central nervous system. The response to local radiotherapy of intracerebral myelomatous deposits has been helpful3 I but intrathecal methotrexate previously failed to control deposits of plasma cell leukaemia in the brain.12
It has been suggested that the lowered temperature of the testes in the scrotum creates a non-anatomical blood-testes barrier making this organ a sanctuary from chemotherapeutic attack and penetration of melphalan into the testes is unknown (personal communication, Wellcome Foundation). The treatment for plasma cell leukaemia deposits in the testes has been surgical. 9 Achieving a response in plasma cell leukaemia with conventional therapy of melphalan and prednisolone is rare but if this occurs, extramedullary relapses especially in sites protected from chemotherapeutic attack should be anticipated.
